Evidence map›Paper›PMID 25630645›Full record

ArticleThe Journal of antimicrobial chemotherapy2015

Risk factors for ambulatory urinary tract infections caused by high-MIC fluoroquinolone-susceptible Escherichia coli in women: results from a large case-control study.

Pinyo Rattanaumpawan, Irving Nachamkin, Warren B Bilker, Jason A Roy, Joshua P Metlay, Theoklis E Zaoutis, Ebbing Lautenbach, CDC Prevention Epicenters Program

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Spatial pattern and risk factors of resistance to important antibiotics amongAntimicrobial stewardship & healthcare epidemiology : ASHE · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Pinyo RattanaumpawanCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand pinyo@mail.med.upenn.edu.
Irving NachamkinDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Warren B BilkerDepartment of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA.
Jason A RoyDepartment of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA.
Joshua P MetlayDivision of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA.
Theoklis E ZaoutisCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA.
Ebbing LautenbachCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
CDC Prevention Epicenters Program
University of Pennsylvania · USMassachusetts General Hospital · US

Funding

Mentoring and patient-oriented research in antimicrobial resistanceK24AI080942 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI LAUTENBACH, EBBING · 2009 to 2013
$853k
Urinary Infections due to Escherichia Coli with Reduced Quinolone SusceptibilityR21AI103497 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI LAUTENBACH, EBBING · 2013 to 2014
$430k
NCEZID CDC HHS U54-CK000163NIAID NIH HHS K24-AI080942NIAID NIH HHS R21 AI103497NIAID NIH HHS R21-AI103497
6 · The paper itself

Abstract

objectivesThe prevalence of high-MIC fluoroquinolone-susceptible Escherichia coli (FQSEC) has been increasing. These isolates are one step closer to full fluoroquinolone (FQ) resistance and may lead to delayed response to FQ therapy. Our study aimed to investigate the epidemiology of high-MIC FQSEC in ambulatory urinary tract infections (UTIs). PATIENTS AND

methodsA case-control study was conducted at outpatient services within the University of Pennsylvania Health System, Philadelphia. All female subjects with non-recurrent UTI caused by FQSEC (levofloxacin MIC < 4 mg/L) were enrolled. Cases were subjects with high-MIC FQSEC UTI (levofloxacin MIC >0.12 but < 4 mg/L) and controls were subjects with low-MIC FQSEC UTI (levofloxacin MIC ≤0.12 mg/L). Data on microbiology results and baseline characteristics were extracted from electronic medical records.

resultsDuring the 3 year study period (May 2008-April 2011), 11 287 episodes of E. coli bacteriuria were identified. The prevalence of FQSEC, FQ-intermediate susceptible E. coli and FQ-resistant E. coli was 75.0%, 0.4% and 24.6%, respectively. A total of 2001 female subjects with FQSEC UTI were enrolled into our study (165 cases and 1836 controls). Independent risk factors for high-MIC FQ susceptibility included Asian race (OR = 2.92; 95% CI = 1.29-6.58; P = 0.02), underlying renal disease (OR = 2.18; 95% CI = 1.15-4.14; P = 0.02) and previous nitrofurantoin exposure (OR = 8.86; 95% CI = 1.95-40.29; P = 0.005).

conclusionsAsian race, underlying renal disease and previous exposure to nitrofurantoin were identified as independent risk factors for high-MIC FQSEC. There may be some factors that are more common in Asians, which may result in the selection of high-MIC FQSEC. Further studies are necessary to explore these findings.

Indexed as

Ambulatory CareAdolescentAdultAgedAnti-Bacterial AgentsCase-Control StudiesEscherichia coliEscherichia coli InfectionsFemaleFluoroquinolonesHumansIncidenceMicrobial Sensitivity TestsMiddle AgedPhiladelphiaRisk FactorsAnti-Bacterial AgentsFluoroquinolonesEscherichia colifluoroquinolone resistanceUTIs

Identifiers

PMID25630645
PMCPMC4398470
OpenAlexW2120924634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.